Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial - The Lancet Oncology

Immunotherapy Drugs Shrink Brain Metastases from Melanoma - NCI

PDF) Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Addition of nivolumab, ipilimumab to chemotherapy extends OS in NSCLC with brain metastases

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial - The Lancet Oncology

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study - ScienceDirect

Decoding molecular programs in melanoma brain metastases

Actualizaciòn en el tratamiento de metàstasis cerebrales por melanoma

MBM - Melanoma Brain Metastases

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Combination immunotherapy shrinks metastatic brain cancer